Progenra’s portfolio of novel first in class small molecules includes selective E3 ligase molecular glues and PROTAC® molecules, and we welcome industry partners to execute mutually beneficial licensing agreements for our small molecule portfolio assets. Progenra wishes to continue working with academic institutions to further dissect the ubiquitin proteasome system (UPS) and we welcome discussions with commercial and academic entities focusing on in-licensing technologies and/or compounds that are complementary to our internal development strategy.
Partnering with Progenra includes:
- Unparalleled expertise in the ubiquitin proteasome system
- Small molecule (enzyme modulator and PROTAC) drug candidate assets in
Research collaboration with Progenra allows Progenra’s partners to overcome the greatest barriers to working in the ubiquitin field.
Please contact the Progenra Business Development Team for enquiries: email@example.com.